Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
227 Leser
Artikel bewerten:
(2)

FDA, State of Maryland, and Baugher Enterprise warn consumers to avoid Baugher's Apple Cider / Cider may be related to outbreak of E. coli infections

SILVER SPRING Md., Nov. 5, 2010 /PRNewswire-USNewswire/ --

Fast Facts -- Baugher's Apple Cider in half gallon and gallon containers, offered for sale in Maryland and Pennsylvania, is preliminarily linked with an outbreak of E. coli O157:H7 infections. -- Consumers who have any of this cider should not drink it and should dispose of the cider in a manner that prevents people or animals, including wild animals, from consuming it. -- Most people infected with E. coli O157:H7 develop diarrhea and abdominal cramps, but some illnesses may last longer and can be more severe. While most people recover within a week, some may develop a severe infection. Rarely, as symptoms of diarrhea improve, a type of kidney failure called hemolytic uremic syndrome (HUS) can occur; this can happen at any age, but is most common in children under 5 years old and in older adults. People with HUS should be hospitalized immediately, as their kidneys may stop working and they may be at risk for other serious health problems. -- As of Thursday, Nov. 4, 2010, 7 persons infected with the outbreak strain of E. coli O157:H7 have been reported from Maryland since October 22. There have been 3 reported hospitalizations, 1 possible case of HUS and no deaths. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) What is the Problem?

The U.S. Food and Drug Administration and the Maryland Department of Health and Mental Hygiene (DHMH) join Baugher Enterprise in warning consumers to not consume Baugher's Apple Cider, as this cider may be associated with an outbreak of E. coli O157:H7 infections. The cider was available for sale in Maryland and Pennsylvania.

What are the Symptoms of Illness/Injury?

Most people infected with E. coli O157:H7 develop diarrhea and abdominal cramps, but some illnesses may last longer and can be more severe. While most people recover within a week, some may develop a severe infection. Rarely, as symptoms of diarrhea improve, a type of kidney failure called hemolytic uremic syndrome (HUS) can occur; this can happen at any age but is most common in children under 5 years old and in older adults. People with HUS should be hospitalized immediately, as their kidneys may stop working and they may be at risk for other serious health problems.

What Do Consumers Need To Do?

Do not drink Baugher's Apple Cider. Consumers should dispose of the cider in a manner that prevents people or animals, including wild animals, from consuming it.

Anyone who experienced signs of E. coli O157:H7 infection should contact his or her health care provider immediately. Health care providers should report any suspected infection to state or local public health authorities right away.

Where is it Distributed?

Baugher Enterprise reports that the cider is distributed throughout Maryland and in the Gettysburg area of Pennsylvania.

What is Being Done to Protect Consumers?

The FDA, DHMH and Baugher Enterprise are working together on the investigation. Initial public notification was made by DHMH on Nov. 4, 2010. FDA and the DHMH will continue to update the public with more information as soon as it is available. The FDA, in conjunction with the DHMH, has initiated an investigation at the Baugher Enterprise production facility.

In addition, Baugher Enterprise has voluntarily recalled the cider from its distributors.

The information in this press release reflects FDA's best efforts to communicate what the manufacturer has reported to FDA.

For more information: Maryland Department of Health and Mental Hygiene News Release http://www.fda.gov/Safety/Recalls/ucm232878.htm Baugher Enterprise Inc. News Release

http://www.fda.gov/Safety/Recalls/ucm232977.htm?utm_source=twitterfeed&utm _medium=twitter

Juice and Cider: Make sure they're safe http://www.foodsafety.gov/blog/apple_cider.html Media Inquiries: Doug Karas, 301-796-2805, douglas.karas@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA

Photo: http://photos.prnewswire.com/prnh/20090824/FDALOGO
http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO
PRN Photo Desk, photodesk@prnewswire.com

U.S. Food and Drug Administration

CONTACT: Media Inquiries: Doug Karas, +1-301-796-2805,
douglas.karas@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA

Web Site: http://www.fda.gov/

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.